Apptly Health Technologies Announces Strategic Partnership with BioTrax AI to Bring Precision Longevity Tools to Its Physician Network

Partnership introduces BioTrax AI's clinical longevity platform to more than 7,000 physicians across the Apptly direct-pay marketplace


VANCOUVER, British Columbia and PALO ALTO, Calif. and BOSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Apptly Health Technologies Corp. (CSE: APPT) (OTCQB: APTHF) (FSE: 4KL0) (“Apptly” or the “Company”), operator of the Apptly direct-pay healthcare marketplace, today announced a strategic partnership with BioTrax AI, Inc. (“BioTrax AI”), a provider of a clinical software platform built for longevity and preventive medicine practices. Under the terms of the agreement, Apptly will introduce BioTrax AI’s advanced platform to the more than 7,000 independent physicians within its network, providing them with a purpose-built clinical infrastructure designed for preventive and longitudinal care.

Physicians practicing outside of traditional insurance frameworks have rapidly expanded into preventive and longevity medicine, where patient health is measured and optimized across years rather than individual visits. However, most practitioners currently document the continuous work within the legacy electronic health record (EHR) systems built strictly for episodic, claims-driven encounters. This creates a critical disconnect: the clinical strategy is longitudinal, but the record is not.

BioTrax AI bridges this gap directly. Its AI-native platform unifies laboratory testing, proactive results management, longitudinal biomarker tracking, clinical workflows, and automated documentation into a single, cohesive interface. The platform also features a connected patient dashboard that aggregates health metrics, wearable device data, and secure physician-patient communication. Combined, these features establish a shared longitudinal record that aligns physicians and patients over time.

Apptly expects to launch a phased rollout of the BioTrax AI platform to its network in the fourth quarter of 2026. The rollout will feature direct physician outreach, educational webinars, and a dedicated platform presence on the Apptly marketplace.

The partnership is non-exclusive, ensuring that physicians retain full discretion over whether to adopt the software. No changes will be made to how physicians list, price, or deliver care on the Apptly marketplace.

Executive commentary

“I built Apptly because patients deserve a direct line to their doctor, and doctors deserve to practice without a layer in between telling them how. The physicians in our network keep telling us the same thing about prevention work. The clinical thinking is there, but the tooling is not. BioTrax AI was built by a clinician who has lived inside that gap, and that is why we are making this introduction to our network.” - Dr. Paula Muto, Founder and Chief Executive Officer of Apptly Health Technologies Corp. and practicing vascular surgeon.

“BioTrax AI grew out of my two decades of practicing preventive medicine and building digital tools for physicians. Longevity care unfolds over years, so its technology has to connect everything: testing, biomarker trends, wearables, patient communication, and ongoing care. We built BioTrax AI for our colleagues, and this partnership puts an integrated clinical platform and patient dashboard in the hands of independent physicians advancing longevity care.” - Dr. Reena Bhargava, Co-Founder and CEO, BioTrax AI.

“We built BioTrax AI as an AI-native system to help improve operational efficiency and clinical decision-making for practices. Reaching a network of this scale allows us to serve diverse clinical workflows and continue improving the platform alongside the physicians using it.” - Gautam Bhargava, Ph.D., Co-Founder, CTO, BioTrax AI.

About BioTrax AI

BioTrax AI is the clinical operating system for physician-led preventive longevity care. The Palo Alto, California-based company builds software for independent longevity, preventive, and direct-care practices, bringing advanced testing and results management, longitudinal biomarker tracking, clinical workflows, and AI-assisted documentation together with a connected patient dashboard for health, wearable, and communication data. BioTrax AI operates as a technology company and HIPAA Business Associate, while physicians retain full clinical decision-making authority. The company was co-founded by Reena Bhargava, MD, FACP, and Gautam Bhargava, PhD. More information is available at biotrax.ai.

About Apptly Health Technologies Corp.

Apptly Health Technologies Corp. operates Apptly, a direct-pay healthcare marketplace connecting patients with board-certified physicians at transparent, published prices without insurance intermediaries. Founded by practicing vascular surgeon Dr. Paula Muto, Apptly serves patients and physicians across specialties throughout the United States. More information is available at apptlyhealth.com.

Contacts

Investor Relations, Apptly Health Technologies Corp.
Media, Apptly Health Technologies Corp.
Meghna Deshraj | Meghna@apptlyhealth.com | 973-369-8052

Media, BioTrax AI
Paige Goldstein | marketing@biotrax.ai

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the anticipated rollout of the BioTrax AI platform to physicians in the Apptly network, the expected timing of that rollout, and the anticipated benefits of the partnership to either party. Forward-looking statements are based on assumptions that management considers reasonable as of the date of this release, including assumptions regarding physician interest and adoption, the continued operation of both platforms, and the absence of material changes in the regulatory environment. Forward-looking statements are subject to known and unknown risks and uncertainties, and actual results may differ materially. Physician adoption is discretionary and no assurance can be given that any particular level of adoption, usage, or revenue will result from the partnership. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.


GlobeNewswire